Patient characteristics according to the initial prednisone-equivalent dose of glucocorticoids for treatment of acute GVHD
| Characteristic . | Prednisone-equivalent dose . | |
|---|---|---|
| 1 mg/kg per day . | 2 mg/kg per day . | |
| n | 347 | 386 |
| Age, y (range) | 47 (18-71) | 46 (18-72) |
| Patient sex, female (%) | 151 (44) | 169 (44) |
| Disease risk, n (%) | ||
| Standard | 178 (51) | 194 (50) |
| High | 169 (49) | 192 (50) |
| HLA-mismatch, n (%) | 48 (14) | 87 (23) |
| Donor, n (%) | ||
| Related | 173 (50) | 134 (35) |
| Unrelated | 174 (50) | 252 (65) |
| Conditioning, n (%) | ||
| Myeloablative | ||
| Bu/Cy | 138 (40) | 166 (43) |
| Cy/TBI | 102 (29) | 133 (34) |
| Other | 46 (13) | 31 (18) |
| Nonmyeloablative | 61 (18) | 56 (15) |
| Median days to therapy after GVHD diagnosis (range) | 2 (0-92) | 1 (0-77) |
| Median days to therapy after transplantation (range) | 30 (8-118) | 21 (5-114) |
| GVHD grade at onset, n (%) | ||
| I | 31 (9) | 38 (10) |
| IIa | 238 (69) | 118 (31) |
| IIb | 69 (20) | 167 (43) |
| III | 9 (3) | 62 (16) |
| IV | 0 (0) | 1 (< 1) |
| GVHD organ site involved at onset, n (%) | ||
| Skin | 143 (41) | 285 (74) |
| Gut | 288 (82) | 249 (65) |
| Liver | 26 (7) | 89 (23) |
| Limited to the skin | 54 (16) | 106 (27) |
| Limited to the gut | 192 (55) | 69 (18) |
| Biopsy before GVHD treatment, n (%) | 328 (95) | 303 (79) |
| Hospitalized at onset of GVHD treatment, n (%) | 164 (47) | 268 (69) |
| Year of transplantation, n (%) | ||
| 2000 | 58 (17) | 84 (22) |
| 2001 | 50 (14) | 87 (23) |
| 2002 | 61 (18) | 66 (17) |
| 2003 | 65 (19) | 57 (15) |
| 2004 | 61 (18) | 52 (13) |
| 2005 | 52 (15) | 40 (10) |
| Tacrolimus prophylaxis, n (%) | 54 (16) | 85 (22) |
| BDP use, n (%) | ||
| Never | 175 (50) | 302 (78) |
| Initiated with systemic therapy | 134 (39) | 27 (7) |
| Characteristic . | Prednisone-equivalent dose . | |
|---|---|---|
| 1 mg/kg per day . | 2 mg/kg per day . | |
| n | 347 | 386 |
| Age, y (range) | 47 (18-71) | 46 (18-72) |
| Patient sex, female (%) | 151 (44) | 169 (44) |
| Disease risk, n (%) | ||
| Standard | 178 (51) | 194 (50) |
| High | 169 (49) | 192 (50) |
| HLA-mismatch, n (%) | 48 (14) | 87 (23) |
| Donor, n (%) | ||
| Related | 173 (50) | 134 (35) |
| Unrelated | 174 (50) | 252 (65) |
| Conditioning, n (%) | ||
| Myeloablative | ||
| Bu/Cy | 138 (40) | 166 (43) |
| Cy/TBI | 102 (29) | 133 (34) |
| Other | 46 (13) | 31 (18) |
| Nonmyeloablative | 61 (18) | 56 (15) |
| Median days to therapy after GVHD diagnosis (range) | 2 (0-92) | 1 (0-77) |
| Median days to therapy after transplantation (range) | 30 (8-118) | 21 (5-114) |
| GVHD grade at onset, n (%) | ||
| I | 31 (9) | 38 (10) |
| IIa | 238 (69) | 118 (31) |
| IIb | 69 (20) | 167 (43) |
| III | 9 (3) | 62 (16) |
| IV | 0 (0) | 1 (< 1) |
| GVHD organ site involved at onset, n (%) | ||
| Skin | 143 (41) | 285 (74) |
| Gut | 288 (82) | 249 (65) |
| Liver | 26 (7) | 89 (23) |
| Limited to the skin | 54 (16) | 106 (27) |
| Limited to the gut | 192 (55) | 69 (18) |
| Biopsy before GVHD treatment, n (%) | 328 (95) | 303 (79) |
| Hospitalized at onset of GVHD treatment, n (%) | 164 (47) | 268 (69) |
| Year of transplantation, n (%) | ||
| 2000 | 58 (17) | 84 (22) |
| 2001 | 50 (14) | 87 (23) |
| 2002 | 61 (18) | 66 (17) |
| 2003 | 65 (19) | 57 (15) |
| 2004 | 61 (18) | 52 (13) |
| 2005 | 52 (15) | 40 (10) |
| Tacrolimus prophylaxis, n (%) | 54 (16) | 85 (22) |
| BDP use, n (%) | ||
| Never | 175 (50) | 302 (78) |
| Initiated with systemic therapy | 134 (39) | 27 (7) |
Bu indicates busulfan; Cy, cyclophosphamide; TBI, total body irradiation; and BDP, beclomethasone diproprionate.
Disease risk: standard refers to aplastic anemia, chronic myeloid leukemia in chronic phase, myelodysplastic syndromes without excess blasts, and leukemia and lymphoma in remission. High refers to all other hematologic malignancies.